1. Introduction {#sec1}
===============

Thyroid cancer, particularly papillary thyroid carcinoma, is considered to be one of the most common malignancies. Its incidence increases in differed geographic regions of the world in the past decade. Increase in incidence of thyroid cancer is one of the top malignancies in the United States \[[@B1]\]. Rise in incidence observed may partly be accounted for improvement in diagnosis. It is indicated that papillary thyroid carcinoma is attributed to the entire increase significantly by separated researches \[[@B2], [@B3]\]. Although the thyroidectomy, thyroid-stimulating hormone suppression therapy, and radioiodine remnant ablation (RAI) ameliorate the disease-free survival, a group of patients still cannot benefit from the traditional therapy. 5% of patients with distant metastasis are refractory to RAI \[[@B4]\]. It is believed that the tumor cells lost their ability in uptake of the iodide and side effects of ^131^I therapy of salivary gland dysfunction (\>40%), abnormally dry eyes (25%), and transient fertility reduction (20%) affect the patient living quality seriously \[[@B5]\]. Besides, patients are contraindicated to thyroidectomy who suffer from cardiac or respiratory disease, dialysis-dependent renal failure, anticoagulant therapy, obstructive sleep apnea, mental impairment, thyrotoxicosis, and morbid obesity \[[@B6]\]. The postoperative complications of surgery are quite common including hypocalcemia (20%--30%) and recurrent laryngeal nerve injury (5%--11%) and risk for nerve injury increased significantly by reoperation \[[@B7]\]. Due to the limits of traditional therapy, more efforts are recalled for new drugs development with higher efficiency and fewer side effects. It is protein kinases that function as core in signaling pathways participating in tumor proliferation, invasion, metastasis, and tumor microenvironment formation in major types of tumors, including thyroid cancer pathogenesis.

It has been identified that in papillary thyroid carcinoma several molecular changes exist: rearranged during transfection (RET)/papillary thyroid carcinoma gene rearrangements, BRAF (B-RAF protooncogene, serine/threonine kinase) gene mutations, RAS (rat sarcoma) mutations, and vascular endothelial growth factor receptor 2 angiogenesis pathways activation. BRAF oncogene mutation occurred in approximately 45% to 70% of patients with papillary thyroid carcinoma and VEGF overexpression is frequently found in tumors that originated in the thyroid \[[@B8]--[@B11]\]. In the landmark DECISION study, Sorafenib, a multikinase inhibitor of RET/RAS/RAF pathway, VEGF receptors 2 and 3, improved the progression-free survival by 3 months, from 5.8 months to 10.8 months, compared with placebo \[[@B12]\]. It emerged as a potentially effective option and approved by Food and Drug Administration (FDA) as a receptor tyrosine kinase inhibitor as treatment of differentiated thyroid cancer refractory to RAI.

We aimed to investigate the protein kinase expression difference between papillary thyroid carcinoma and normal thyroid and possible molecular mechanisms underlying PTC. We try to provide valuable information on PTC associated protein kinases for potential therapeutic targets.

2. Method {#sec2}
=========

2.1. Identify Differentially Expressed Protein Kinases in PTC {#sec2.1}
-------------------------------------------------------------

We searched in the NCBI (National Center for Biotechnology Information) Gene Expression Omnibus (GEO) database ([https://www.ncbi.nlm.nih.gov/geo/](https://www.ncbi.nlm.nih.gov/geo)) to retrieve the genome-wide expression profile of human papillary thyroid carcinoma. The original dataset from GSE27155 including 51 human specimens of PTC and 4 specimens of normal thyroid tissues was downloaded and array from the Affymetrix platform was processed. To discover the differential gene expression the significance analysis of microarrays (SAM) was applied. False discovery rate (FDR) less than 0.05 was considered to present significant difference. All the differentially expressed genes were mapped onto The Human Protein Kinase Reference Database to establish differentially expressed kinases in PTC. Then we conducted systematic screening of the literature in PubMed for researches concerning the association between papillary thyroid carcinoma and protein kinases.

2.2. Database-Based GO and Pathway Enrichment Analysis and Literature Review {#sec2.2}
----------------------------------------------------------------------------

Each protein kinase\'s corresponding GO term or ID in the GO database was validated by AmiGO search engine. Gene ontology (GO) enrichment analysis was used to evaluate the potential function for the differentially expressed genes. The pathway was analyzed by the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. To obtain putatively valuable new kinase targets for the treatment of PTC, we conducted a systematic literature screening of all the protein kinases. The keywords in the title and abstracts "each protein kinase," "cancer," and "papillary thyroid carcinoma" were used. Finally, we drew the picture of interactions among kinases, signaling pathways, and GO terms.

2.3. Screening Kinase Inhibitors for Predicted Kinases Involved in PTC {#sec2.3}
----------------------------------------------------------------------

To obtain new potentially valuable kinase inhibitors for PTC therapy, we systematically screened all available multikinase and specific kinase inhibitors (<http://www.selleckchem.com/>). We than retrieved the number of publications related to each kinase inhibitor and carcinoma.

3. Results {#sec3}
==========

3.1. Establishment of Differentially Expressed Protein Kinases {#sec3.1}
--------------------------------------------------------------

There are 518 human protein kinases in total in the protein kinase database. Amongst them, 110 kinases were predicted to be related to papillary thyroid carcinoma in our network. We tried to delineate a network of protein kinases engaged in PTC. Several kinase families exhibited correlation to pathophysiological process of PTC via the GO database. Here, we presented a map of these kinases to visualize their relationship in biological process.

3.2. Functional Analysis and Literature Review {#sec3.2}
----------------------------------------------

GO and KEGG enrichment analyses were conducted in the differentially expressed kinases. Kinases with a result of less than 0.05 in GO terms and pathways with FDR-value were considered to be the most valuable possible targets and were applied for further analysis. Study in different kinds of cancer mainly focused on the roles of SRC (v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)), MAPK (mitogen-activated protein kinase), MET (met protooncogene (hepatocyte growth factor receptor)), ATM (ataxia telangiectasia mutated), PDGFRa (platelet-derived growth factor receptor, alpha polypeptide), ErbB (v-erb-a erythroblastic leukemia viral oncogene homolog), MAP2 K1 (bromodomain containing 4), TGFbR1 (transforming growth factor, beta receptor 1), and CDK6 (cyclin-dependent kinase 6) (shown in [Figure 1](#fig1){ref-type="fig"}). Coincidently, the above-predicted kinases were confirmed with differentially protein kinases expression investigated in PTC patients ([Figure 2](#fig2){ref-type="fig"}). 39 GO terms were annotated and presented as common biological process among all these kinases ([Table 1](#tab1){ref-type="table"}). Finally, we built networks to investigate the relationship among kinases, signaling pathways, and GO terms (Figures [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}).

3.3. Potential Novel Kinase Inhibitors for PTC {#sec3.3}
----------------------------------------------

To investigate novel kinase inhibitors for the treatment of PTC, we conducted a literature review of the cancer-related research including 20 focused kinases involved in our network. The publication number could indicate the extent of the research on kinase inhibitor use in cancer treatment ([Table 2](#tab2){ref-type="table"}).

4. Discussion {#sec4}
=============

Tyrosine kinases, classified as receptor tyrosine kinase (RTK) and nonreceptor tyrosine kinase (nRTK), are essential mediators of signaling pathways through catalyzing phosphorylation of selecting tyrosine residues with ATP, leading to cell proliferation differentiation, migration, and metabolism. Recently, it has come in vogue to use tyrosine kinases inhibitors as conceivable anticancer drug and several tyrosine kinase inhibitors (TKIs) have been approved by FDA in neoplastic human disease, particularly in the thyroid cancer. The largest subfamily of nRTKs, Src family kinase (SFK), was closely related to PTC indicated by our network. It has been found that Src and Lyn are expressed in thyroid cancer cells and Src is overexpressed and activated in thyroid cancer \[[@B13]\]. Src also plays an important role in tumor metastasis due to its function in regulation of cytoskeleton, cell migration, adhesion, and invasion through phosphorylation of focal adhesion kinase (FAK), a component of focal adhesion complexes \[[@B14]--[@B16]\]. BTK and HCK expressions are upregulated in invasive thyroid cancer compared to matched normal group, which is similar to Src. Dasatinib, a FDA-approved SFK inhibitor, can block PTC tumor growth by more than 90% and significantly inhibited metastasis \[[@B13]\]. Apart from Src family, several kinase families were also annotated in the GO analysis: Bruton agammaglobulinemia tyrosine kinase (BTK), Janus Kinase 3 (JAK3), and c-src tyrosine kinase (CSK). However, the role of theses kinase families in PTC has not been reported yet and requires further elucidation.

It is epidermal growth factor family member, one of the receptor tyrosine kinase (RTK) families, that not only induces cell growth but also contributes to cell migration and proliferation via its downstream signaling pathways such as mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT pathways, which leads to cell migration, adhesion, and proliferation \[[@B17]\]. Several independent studies documented that EGFR mRNA expression is increased in PTC compared with benign thyroid lesions and EGFR protein expression is upregulated simultaneously \[[@B18]--[@B21]\]. Besides, EGFR expression was noted to possess prognostic value for that its expression was significantly associated with lymph node metastasis in a retrospective analysis of 168 patients with PTC \[[@B22]\]. Platelet-derived growth factor (PDGF)/PDGF receptor (PDGFR) system, another member of RTK class III, contributes to tumor formation, cell survival, growth, and proliferation \[[@B23]--[@B25]\]. Previous studies presented that PDGFR-*α* was upregulated at both mRNA and protein levels in thyroid carcinoma cell lines compared with benign tissues of thyroid nodular hyperplasia \[[@B25]\]. It was revealed that association of PDGFR-*α* with aggressive and lymph node metastatic phenotype in PTC was achieved through both the MAPK/ERK and PI3K/Akt pathways \[[@B26]\].

MET gene is one of the useful molecular markers for PTC \[[@B27]\] and elevated at RNA and protein level in frozen thyroid tissue samples and fine-needle aspiration biopsy \[[@B28]\]. However, no expression of c-met and its ligand hepatocyte growth factor/scatter factor (HGF/SF) could be detected in normal thyroid tissue \[[@B29]\]. MET could strengthen malignancy by its interaction with vascular endothelial growth factor receptor (VEGFR) which induces angiogenesis \[[@B30]\]. In the past decade, several MET kinase inhibitors have been developed, for example, the Tivantinib. Tivantinib impedes ligand-mediated MET autophosphorylation to reduce invasion, metastasis, and proliferation \[[@B31], [@B32]\]. Several Phase II trials on Tivantinib have been in process treating different tumor types, in which Tivantinib treatment showed antitumor effects with monotherapy in microphthalmia transcription factor family associated tumors \[[@B33]\] and prolonged progression-free survival in nonsmall-cell lung cancer \[[@B34]\]. MET may also be exhibited to be overexpressed in PTC with extremely limited investigation done in thyroid carcinoma. Cabozantinib is another FDA-approved tyrosine kinase inhibitor targeting three important pathways: MET, vascular endothelial growth factor (VEGF), and rearranged during transfection (RET) for the treatment of metastatic medullary thyroid cancer. It has shown significant effects in prolongation of progression-free survival with acceptable safety profile \[[@B35]\]. Based on the above trials, inhibiting of MET pathway (or in combination with other kinase inhibitors) is quite a possible way to improve the prognosis of PTC.

Mitogen-activated protein kinase (MAPK) is regarded as a member of serine/threonine protein kinases and a canonical pathway activated by BRAF, RET, or TRK and RAS mutations through Ras-Raf-MEK-ERK cascade in PTCs \[[@B36]--[@B38]\]. MAPK members act as key regulators for cell growth, proliferation, and differentiation during cancer progression. Previous studies have reported that matrix metalloproteinases (MMPs) were modulated according to the intensity of MAPK pathway activation which partly explained the mechanism of increased propensity of tumor invasion in PTC patients carrying BRAF mutation \[[@B39], [@B40]\]. The phosphorylation status of MAPK molecule, p38 MAPK signaling pathway, could be achieved by high expression of family with sequence similarity 172, member A (FAM172A) in human PTC which induced cell proliferation. However, the effects following MAPK molecule phosphorylation can be attenuated markedly by inhibitor of p38 MAPK, SB202190 \[[@B41]\]. Other two types of the mitogen-activated protein kinase (MAPK) cascade, namely, MAPK kinase (MAPKK/MEK) and MAPK kinase kinase (MAPKKK/MEKK) which play important roles in cell growth, were included in our network. It is well known that these two upstream molecules of MAPKs regulate cell proliferation and apoptosis by activating MAPK pathways \[[@B42]\]. Strikingly, inhibitors of MEK (PD0325901) may also contribute to restoration of tumor cells RAI uptake by recovery expression of Na^+^/I^−^ symporter (NIS) protein \[[@B43]\]. The propensity of maintaining stability of NIS by MEK was proved again in human breast cancers \[[@B44]\].

Tumors are characterized for uncontrolled cell division. Cyclin-dependent kinases (CDKs) responsible for controlling cell cycle were expected to become an effective therapeutic target. Various evidences point to a crucial role of an aberrant cyclin D1-CDK4/6 complex in initiation and progression of cancers. Cyclin D1 expressed in about 30% of PTC carcinoma \[[@B45]\] and its overexpression correlate with metastasis of PTC \[[@B46]\]. P27^KIP1^, a CDK inhibitor that could impair the activity of cyclin-CDK complex, was found to be reduced in metastatic forms of PTC \[[@B47], [@B48]\]. Therefore, CDKs are attractive set of targets for novel anticancer drug development.

To conclude, protein kinases play essential roles in controlling cellular growth, cell proliferation, and cell death and have been found to participate in human neoplastic diseases. Our network presented potential kinases involved in several aspects of papillary thyroid carcinoma development including invasion, metastasis, progression, and sensitivity to RAI. Many of the kinase inhibitors are undergoing clinical trials while several have already been approved for treatment of PTC and/or other types of cancer. In addition to the traditional kinases applied in PTC, we provided more kinases which have not been equivocally investigated but are potentially effective options in the treatment of PTC. Therefore, targeting abnormal activation of tyrosine kinases is a promising way to treat PTC.
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###### 

The functions of the most discussed protein kinases involved in PTC.

  Function                                                           Kinases
  ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protein amino acid phosphorylation                                 EGFR, MAPK1, MEK, MEKK, MEKKK, CDKL1, PDGFRA, FGFR2, ERBB4, ERBB3, SRC, TGFBR1, MET, ATM, CSK, LYN, CDK9, CDK6, CDK7, LCK, HCK, FLT4, FYN, JAK3
  Phosphorylation                                                    BTK, MEKKK, MEKK, EGFR, MAPK1, PDGFRA, FGFR2, ERBB4, ERBB3, EPHB1, SRC, TGFBR1, MET, ATM, CSK, CDK6, LCK, HCK
  Phosphorus metabolic process                                       BTK, MEK, MEKK, EGFR, MAPK1 PDGFRA, FGFR2, ERBB4, ERBB3, EPHB1, SRC, TGFBR1, MET, ATM, CSK, LYN, CDK6, LCK, FYN, JAK3
  Phosphate metabolic process                                        BTK, MEKK, MEK, EGFR, MAPK, PDGFRA, FGFR2, FGR, ERBB4, ERBB3, EPHB1, SRC, TGFBR1, MET, ATM, NTRK3, NTRK2, DYRK1A, CSK, LYN, CDK9, CDK6, CDK7, LCK, HCK, FYN JAK3
  Protein kinase cascade                                             ERBB3, SRC, BTK, MEKK, MEK, EGFR, TGFBR1, MET, MAPK, FYN, JAK3
  Intracellular signaling cascade                                    BTK, MEKK, CSK, MEK, EGFR, LYN, CDK, MEKKK, MAPK1, ERBB3, SRC, TGFBR1, MET, ATM, FYN, JAK3
  Protein amino acid autophosphorylation                             EGFR, TGFBR1, MET, MEKK, FYN, PDGFRA
  Enzyme linked receptor protein signaling pathway                   FGFR2, ERBB4, ERBB3, SRC, EPHB1, MEKK, AKT2, EGFR, TGFBR1, MET PDGFRA, JAK3
  Transmembrane receptor protein tyrosine kinase signaling pathway   EGFR, FGFR2, ERBB4, ERBB3, MET, SRC, EPHB1, PDGFRA, AKT2
  Peptidyl-tyrosine phosphorylation                                  ERBB4, LYN, ERBB3, FYN, PDGFRA, JAK3, SRC, BTK
  MAPKKK cascade                                                     EGFR, MEK, TGFBR1, MET, MAPK, MEKK
  Peptidyl-tyrosine modification                                     ERBB4, LYN, ERBB3, FYN, PDGFRA, JAK3, SRC, BTK
  Regulation of phosphorylation                                      EGFR, MEK, LYN, TGFBR1, MET, CDK7, MEKK
  Regulation of transferase activity                                 EGFR, MEK, TGFBR1, MET, CDK7, MEKK
  Regulation of phosphate metabolic process                          EGFR, MEK, LYN, TGFBR1, MET, CDK, MEKK
  Regulation of phosphorus metabolic process                         EGFR, MEK, LYN, TGFBR1, MET, CDK, MEKK
  Regulation of protein kinase activity                              EGFR, MAP2K1, TGFBR1, MET, CDK7, MAP3K5, MAP3K1, MAP2K6
  Regulation of kinase activity                                      EGFR, MAP2K1, TGFBR1, MET, CDK7, MAP3K5, MAP3K1, MAP2K6
  Regulation of cell motion                                          EGFR, LYN, MAP2K1, ERBB4, TGFBR1, MAPK1, MAP3K1, PDGFRA,
  Positive regulation of cell motion                                 EGFR, MAPK1, ERBB4, MAP2K1, LYN, TGFBR1, PDGFRA,
  Regulation of cell migration                                       EGFR, MAPK1, ERBB4, MAP2K1, MAP3K1, PDGFRA,
  Cell surface receptor linked signal transduction                   FGFR2, ERBB4, ERBB3, SRC, EPHB1, MAP3K1, TEK, EGFR, LYN, TGFBR1, MET, MAPK1, FYN, MAPK14, LCK, PDGFRA, JAK3
  Regulation of locomotion                                           EGFR, MAPK1, ERBB4, MAP2K1, MAP3K1, PDGFRA
  Response to hormone stimulus                                       ERBB4, MAP2K1, LYN, ERBB3, TGFBR1, SRC, MAPK1, PDGFRA
  Regulation of MAP kinase activity                                  EGFR, MAP3K5, MAP2K1, MAP3K1, MET, MAP2K6
  Positive regulation of cell communication                          EGFR, LYN, ERBB4, ERBB3, TGFBR1, SRC, MAP3K3, LCK
  Regulation of cell proliferation                                   EGFR, FGFR2, ERBB4, LYN, ERBB3, TGFBR1, CDK6, MAPK1, PDGFRA, CSK, MAP2K5
  Response to organic substance                                      EGFR, ERBB4, MAP2K1, LYN, ERBB3, TGFBR1, SRC, MAPK1, FYN, MAPK14, PDGFRA
  Response to endogenous stimulus                                    ERBB4, MAP2K1, LYN, ERBB3, TGFBR1, SRC, MAPK1, PDGFRA
  Positive regulation of cell proliferation                          EGFR, FGFR2, ERBB4, LYN, TGFBR1, CDK6, MAPK1, PDGFRA, MAP2K5
  Positive regulation of cell migration                              EGFR, MAPK1, ERBB4, MAP2K1, PDGFRA,
  JNK cascade                                                        MAP3K5, MAP3K1, MAP2K4, MAP3K12
  Stress-activated protein kinase signaling pathway                  MAP3K5, MAP3K1, MAP2K4, MAP3K12
  Positive regulation of protein kinase activity                     EGFR, MAP3K5, MAP2K1, MAP3K1, TGFBR1, MET, MAP2K6
  Positive regulation of locomotion                                  EGFR, MAPK1, ERBB4, MAP2K1, PDGFRA
  Positive regulation of kinase activity                             EGFR, MAP3K5, MAP2K1, MAP3K1, TGFBR1, MET, MAP2K6
  Positive regulation of MAP kinase activity                         EGFR, MAP3K5, MAP2K1, MAP3K1, MET, MAP2K6
  Positive regulation of transferase activity                        EGFR, MAP3K5, MAP2K1, MAP3K1, TGFBR1, MET, MAP2K6

###### 

Potential novel kinase inhibitors for the treatment of PTC.

  Kinase                            Kinase inhibitor               Publication number
  --------------------------------- ------------------------------ --------------------
  EGFR                              Gefitinib (ZD1839)             3040
  Erlotinib HCl (OSI-744)           4310                           
  Lapatinib                         1681                           
  Afatinib (BIBW2992)               409                            
  AZD8931 (Sapitinib)               389                            
  AG-1478 (Tyrphostin AG-1478)      273                            
  AG-490 (Tyrphostin B42)           221                            
  PD153035 HCl                      136                            
  Neratinib (HKI-272)               113                            
  Canertinib (CI-1033)              94                             
  Icotinib                          69                             
  AEE788 (NVP-AEE788)               61                             
  Pelitinib (EKB-569)               43                             
  Varlitinib                        32                             
  OSI-420                           31                             
  PD168393                          24                             
  Rociletinib (CO-1686, AVL-301)    23                             
  WZ4002                            18                             
  WHI-P154                          15                             
  CUDC-101                          13                             
  TAK-285                           12                             
  Tyrphostin 9                      8                              
  AST-1306                          5                              
  CL-387785 (EKI-785)               5                              
  AG-18                             2                              
                                                                   
  SRC                               Dasatinib                      1771
  PP2                               345                            
  Bosutinib (SKI-606)               207                            
  Saracatinib (AZD0530)             126                            
  SU6656                            64                             
  KX2-391                           8                              
  NVP-BHG712                        2                              
  Dasatinib Monohydrate             2                              
                                                                   
  MAPK                              BMS-536924                     29
                                                                   
  MET                               SU11274                        98
  Foretinib (GSK1363089)            26                             
  SGX-523                           7                              
  NPS-1034                          2                              
  NVP-BVU972                        2                              
                                                                   
  ATM                               AZD8055                        66
  KU-55933 (ATM Kinase Inhibitor)   42                             
  KU-60019                          9                              
                                                                   
  CDK6                              Flavopiridol (Alvocidib) HCl   374
  PD-0332991                        137                            
  LY2835219                         9                              
  LDC000067                         1                              
                                                                   
  TGFbR1                            SB431542                       114
  SD-208                            25                             
  SB505124                          10                             
  EW-7197                           8                              
  SB525334                          6                              
  D 4476                            2                              
  RepSox                            1                              
  GW788388                          1                              
                                                                   
  PDGFRa                            Imatinib (STI571)              6749
  Ponatinib (AP24534)               192                            
  Nintedanib (BIBF 1120)            102                            
  Masitinib (AB1010)                52                             
  Lenvatinib (E7080)                28                             
  Quizartinib (AC220)               24                             
  Crenolanib (CP-868596)            19                             
  Amuvatinib (MP-470)               13                             
  ENMD-2076                         12                             
  Telatinib                         11                             
  OSI-930                           8                              
  CP-673451                         5                              
                                                                   
  ErbB4                             AZD8931 (Sapitinib)            12
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